George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.45
Bid: 11.30
Ask: 11.60
Change: 0.20 (1.72%)
Spread: 0.30 (2.655%)
Open: 11.65
High: 11.80
Low: 11.80
Prev. Close: 11.60
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Poolbeg hails approval; EDX links with Thermo Fisher

Tue, 21st Nov 2023 14:39

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Poolbeg Pharma PLC - Clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Says Japanese Patent Office has granted its Immunomodulator 2 patent application, with the formal grant to be received in due course. The claims cover the pharmaceutical pharmaceutical composition of POLB 001 for treating severe influenza in a hospitalised patient in combination with antiviral compounds. Additionally, Poolbeg adds that it has received the fully granted patent for Immunomodulator 1.

----------

EDX Medical Group PLC - Cambridge, England-based company that develops digital diagnostic products and services for the treatment of cancer, heart disease, and infectious diseases - Enters collaboration agreement with Thermo Fisher Scientific EMEA Ltd. According to the deal, both companies will jointly develop and potentially commercialise a number of proprietary qPCR (real-time polymerase chain reaction) assays - including novel and innovative cancer diagnostic solutions. Thermo Fisher's technologies and information translation systems will be used to deliver a number of advanced testing solutions in development at EDX or licensed from partners, including a proprietary assay to enable personalised radiotherapy, and a novel chemotherapy toxicity assay focusing on serious adverse events.

----------

Gelion PLC - London-based Anglo-Australian battery storage company - Signs joint development agreement with Ionblox Inc, a California-based next-generation battery technology company. The agreement aims to deliver safe, high-energy density, lower cost lithium silicon sulfur cells for the global electric vehicle, electrical vertical-takeoff-and-landing and drone markets, before progressing to the stationary energy storage market. Together, Gelion and Ionblox will jointly aim to develop high performance, next-generation LiSiS cells.

----------

Mycelx Technologies Corp - Georgia, US-based clean water and air technology - Receives formal purchase order for the Regen contract, valued at USD5.4 million. The order is for the delivery of a Mycelx-produced water treatment system deploying Regen media. Explains that the system will ensure the unnamed producer is able to reliably discharge clean water overboard in compliance with strict environmental regulations. Expects equipment to be operational in the second half of 2024.

----------

TruFin PLC - London-based financial technology holding company for niche lenders and early payment providers - Says subsidiary, Playstack Ltd, has entered letter of intent to sell intellectual property and assets of its augmented reality and gamification AdTech platform, Interact, to VCI Global Ltd. Notes that whilst transaction terms are yet to be confirmed, any cash consideration is "not expected to be significant" in the context of the wider company. TruFin will provide further updates as appropriate.

----------

UK Oil & Gas PLC - London-based exploration and production company focused on UK and Turkey - Says that the Pinarova joint venture's order of more powerful seven-inch perforating guns arrived in-country last week via airfreight into Istanbul. The new guns will be deployed over the Germik/Hoya section of the site, where strong oil odours at surface were recorded over a 12-hour period during drilling and mobile light oil was recovered from the mud pit.

----------

Dunedin Enterprise Investment Trust PLC - Edinburgh-based UK and overseas companies' investor - Says regulatory approval granted for the realisation of Premier Hytemp, a manufacturer and supplier of engineered metal solutions. The investment in Premier Hytemp is held via DENT's interest in Dunedin Buyout Fund II LP. As of September 30, Dunedin's investment in Premier Hytemp was valued at GBP4.9 million. Following this realisation, it has remaining unlisted investments valued at GBP7.8 million, cash balances of GBP23.3 million, and other net assets of GBP2.9 million. Explains that the board and its advisers are exploring whether to wind-up the company and return cash to shareholders, including the proceeds of the Premier Hytemp realisation, by way of a members' voluntary liquidation. Any such winding-up would require shareholder approval and a further announcement will be made in due course.

----------

Trident Royalties PLC - Mining royalty company - Says all pre-conditions to the Antler Royalty acquisition in the binding acquisition agreement have now been satisfied and that completion has occurred. Previously announced an agreement to buy a 0.9% net smelter return royalty over New World Resources Ltd's Antler copper project in Arizona, US, for a total consideration of AUD11.0 million.

----------

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
20 Mar 2024 16:18

EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Mar 2024 11:10

Poolbeg Pharma to be granted US patent

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.

Read more
19 Feb 2024 14:22

Director dealings: Poolbeg Pharma co-founder ups stake

(Sharecast News) - Poolbeg Pharma revealed on Monday that chairman Cathal Friel had acquired 830,000 ordinary shares in the AIM-listed biopharmaceutical company.

Read more
15 Feb 2024 16:02

TRADING UPDATES: Diversified Energy offers dividend alternative

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
12 Feb 2024 19:44

TRADING UPDATES: Katoro Gold launches fundraising, eyes board shake-up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
12 Feb 2024 14:37

Poolbeg upbeat on research into potential drug market

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery.

Read more
17 Jan 2024 13:58

Poolbeg Pharma hails POLB 001'S potential to treat CRS

(Alliance News) - Poolbeg Pharma PLC on Wednesday noted "promising" results for POLB 001's potential in treating cancer immunotherapy-induced cytokine release syndrome.

Read more
20 Dec 2023 20:00

TRADING UPDATES: K3 Business says cash balances ahead of forecast

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Dec 2023 13:54

Poolbeg makes promising progress with RSV programme

(Sharecast News) - Poolbeg Pharma revealed promising results from the lab-based analysis and prioritisation of respiratory syncytial virus (RSV) drug targets and treatments on Wednesday, driven by its artificial intelligence (AI) programme.

Read more
9 Nov 2023 16:57

IN BRIEF: Poolbeg Pharma appoints former Amryt executives to team

Poolbeg Pharma PLC - Clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Appoints a number of former executives of Amryt Pharma PLC to its leadership team. Poolbeg's Chair, Cathal Friel, co-founded both Poolbeg and Amryt Pharma.

Read more
17 Oct 2023 10:49

Poolbeg Pharma shares up on metabolic drug collaboration agreement

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has agreed to collaborate with an unnamed Nasdaq-listed biopharmaceutical company for the development of an optimised oral drug to treat a metabolic condition.

Read more
2 Oct 2023 14:20

EARNINGS AND TRADING: Kingswood cuts outlook; Poolbeg in patent joy

(Alliance News) - The following is a round-up of updates by London-listed companies, issued last week and not separately reported by Alliance News:

Read more
22 Sep 2023 20:37

TRADING UPDATES: Braemar investigation to end; Marula reports delay

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday, Thursday and Wednesday and not separately reported by Alliance News:

Read more
20 Sep 2023 12:16

Poolbeg gets notice of a new Japan patent

(Sharecast News) - Clinical-stage biopharmaceutical company Poolbeg Pharma announced the receipt of a notice of allowance from the Japanese Patent Office for its Immunomodulator I patent application on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.